IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment MilestoneGlobeNewsWire • 06/14/23
IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program LeadGlobeNewsWire • 06/01/23
IO Biotech Announces an Invited Oral Presentation and Two Poster Presentations with New Preclinical Data for Additional Pipeline Candidates at the Society for Immunotherapy of Cancer's (SITC) 37th Annual MeetingGlobeNewsWire • 11/09/22
IO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients with Resectable TumorsGlobeNewsWire • 11/03/22
IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 37th Annual MeetingGlobeNewsWire • 10/05/22
IO Biotech to Participate in the Morgan Stanley 20th Annual Global Healthcare ConferenceGlobeNewsWire • 09/06/22
IO Biotech Announces Two Presentations at the American Society of Clinical Oncology Annual Meeting 2022GlobeNewsWire • 05/26/22
IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced MelanomaGlobeNewsWire • 05/18/22
IO Biotech Announces Initiation of Phase 2 Trial of IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Multi-Arm Basket TrialGlobeNewsWire • 04/12/22
IO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual MeetingGlobeNewsWire • 04/08/22
IO Biotech Announces Acceptance of Abstract to be Presented at AACR Annual Meeting on April 8, 2022GlobeNewsWire • 03/08/22